CATALYZE THE DISCOVERY OF WIDELY USABLE DIAGNOSTIC CRITERIA BY DEFINING DIGITAL IMAGING BIOMARKERS FOR IDIOPATHIC PULMONARY FIBROSIS AND FIBROTIC INTERSTITIAL LUNG DISEASES, WHICH ARE CURRENTLY EXTREMELY DIFFICULT TO DIAGNOSE AND TREAT BEFORE PERMANENT, AND OFTEN FATAL, DISEASE PROGRESSION HAS OCCURED.